Clinical profile and outcome of cardiac amyloidosis in a Spanish referral center

Revista Espanola de Cardiologia - Tập 74 - Trang 149-158 - 2021
Ángela López-Sainz1,2, Aitor Hernandez-Hernandez1,2, Esther Gonzalez-Lopez1,2, Fernando Domínguez1,2, Maria Alejandra Restrepo-Cordoba1, Marta Cobo-Marcos1,2, Manuel Gómez-Bueno1,2, Francisco Jose Hernandez-Perez1, Juan Francisco Oteo1, Jesus G. Mirelis1,2, Miguel Angel Cavero1, Vanessa Moñivas1, Susana Mingo Santos1, F. Javier de Haro-del Moral3, Isabel Krsnik4, Clara Salas2,5, Belén Bornstein6, Ana Briceño1, Juan Antonio López2,7, Jesús Vázquez2,7
1Servicio de Cardiología, Hospital Universitario Puerta de Hierro Majadahonda, Universidad Autónoma de Madrid, Majadahonda, Madrid, Spain
2Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Spain
3Servicio de Medicina Nuclear, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain
4Servicio de Hematología, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
5Servicio de Anatomía Patológica, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
6Servicio de Bioquímica, Hospital Universitario Puerta de Hierro, Majadahonda, Madrid, Spain
7Centro Nacional de Investigaciones Cardiovasculares (CNIC), Madrid, Spain

Tài liệu tham khảo

García-Pavía, 2011, Amiloidosis. También una enfermedad del corazón, Rev Esp Cardiol, 64, 797, 10.1016/j.recesp.2011.05.003 Gonzalez-Lopez, 2017, Diagnosis and Treatment of Transthyretin Cardiac Amyloidosis. Progress and Hope, Rev Esp Cardiol., 70, 991, 10.1016/j.recesp.2017.05.018 Rapezzi, 2015, Cardiac amyloidosis: the great pretender, Heart Fail Rev., 20, 117, 10.1007/s10741-015-9480-0 Perugini, 2005, Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy, J Am Coll Cardiol., 46, 1076, 10.1016/j.jacc.2005.05.073 Maurer, 2017, Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis, Circulation., 135, 1357, 10.1161/CIRCULATIONAHA.116.024438 Lousada, 2015, Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium, Adv Ther., 32, 920, 10.1007/s12325-015-0250-0 Adams, 2018, Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis, N Engl J Med., 379, 11, 10.1056/NEJMoa1716153 Sayago, 2016, Analysis of diagnostic and therapeutic strategies in advanced cardiac light-chain amyloidosis, J Hear Lung Transplant., 35, 1 Benson, 2018, Inotersen treatment for patients with hereditary transthyretin amyloidosis, N Engl J Med., 379, 22, 10.1056/NEJMoa1716793 Merlini, 2017, AL amyloidosis: from molecular mechanisms to targeted therapies, Hematol Am Soc Hematol Educ Progr., 2017, 1, 10.1182/asheducation-2017.1.1 Maurer, 2018, Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N Engl J Med., 379, 1007, 10.1056/NEJMoa1805689 Falk, 2005, Diagnosis and management of the cardiac amyloidoses, Circulation., 112, 2047, 10.1161/CIRCULATIONAHA.104.489187 Gillmore, 2016, Nonbiopsy diagnosis of cardiac transthyretin amyloidosis, Circulation., 133, 2404, 10.1161/CIRCULATIONAHA.116.021612 Rajkumar, 2014, International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma, Lancet Oncol, 15, e538, 10.1016/S1470-2045(14)70442-5 Ruberg, 2019, Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review, J Am Coll Cardiol., 73, 2872, 10.1016/j.jacc.2019.04.003 Rapezzi, 2009, Systemic cardiac amyloidoses: Disease profiles and clinical courses of the 3 main types, Circulation., 120, 1203, 10.1161/CIRCULATIONAHA.108.843334 Wechalekar, 2016, Systemic amyloidosis, Lancet., 387, 2641, 10.1016/S0140-6736(15)01274-X Krsnik, 2015, Light chain amyloidosis: Experience in a tertiary hospital: 2005-2013, Rev Clin Esp., 215, 1, 10.1016/j.rce.2014.08.013 Gallego-Delgado, 2016, Extracellular volume detects amyloidotic cardiomyopathy and correlates with neurological impairment in transthyretin-familial amyloidosis, Rev Esp Cardiol., 69, 923, 10.1016/j.recesp.2016.02.032 López-Sainz, 2019, Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders, Amyloid., 26, 156, 10.1080/13506129.2019.1625322 Zegri-Reiriz, 2019, Prevalence of cardiac amyloidosis in patients with carpal tunnel syndrome, J Cardiovasc Transl Med., 12, 507, 10.1007/s12265-019-09895-0 Gonzalez-Lopez, 2015, Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction, Eur Heart J., 36, 2585, 10.1093/eurheartj/ehv338 Gonzalez-Lopez, 2017, Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths, Eur Heart J., 38, 1895, 10.1093/eurheartj/ehx043 García-Pavía, 2011, Abordaje familiar en la amiloidosis cardiaca hereditaria por transtiretina, Rev Esp Cardiol., 64, 523, 10.1016/j.recesp.2010.10.018 Gomez-Bueno, 2009, Cardiac amyloidosis: the importance of a multidisciplinary approach, Rev Esp Cardiol., 62, 698, 10.1016/S0300-8932(09)71339-9 Martinez-Naharro, 2017, Magnetic resonance in transthyretin cardiac amyloidosis, J Am Coll Cardiol., 70, 466, 10.1016/j.jacc.2017.05.053 Rowczenio, 2019, Analysis of the TTR gene in the investigation of amyloidosis: A 25-year single UK center experience, Hum Mutat., 40, 90, 10.1002/humu.23669